Souhaitez-vous accéder aux communiqués récents ?

PLYMOUTH MEETING, Pa., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO), today announced that an interim data analysis showed that its INO-5150 cancer immunotherapy...

PLYMOUTH MEETING, Pa., Aug. 23, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the Company will participate in the following upcoming investment conferences:...

PLYMOUTH MEETING, Pa., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today reported financial results for the quarter ended June 30, 2017. Total revenue was $20.4...

PLYMOUTH MEETING, Pa., July 26, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will host a conference call and live webcast to report its 2017 second...

PLYMOUTH MEETING, Pa., July 19, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced the pricing of an underwritten public offering of 12,500,000 shares of its common...

PLYMOUTH MEETING, Pa., July 18, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that it intends to offer and sell $75.0 million of shares of its common stock in an...

PLYMOUTH MEETING, Pa., July 06, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced its DNA-based monoclonal antibody product for flu produced broadly cross-reactive...

PLYMOUTH MEETING, Pa., June 28, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced leadership appointments to support its growth and expanding strategic and...

PLYMOUTH MEETING, Pa., June 19, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Dr. J. Joseph Kim, President & CEO, will participate on a panel, titled...

PLYMOUTH MEETING, Pa., June 15, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that it has completed enrollment of its phase 1 clinical trial in Puerto Rico...